HomeCompareYZCHF vs PFE

YZCHF vs PFE: Dividend Comparison 2026

YZCHF yields 5.20% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $8.8K in total portfolio value· pulled ahead in Year 10
10 years
YZCHF
YZCHF
● Live price
5.20%
Share price
$1.93
Annual div
$0.10
5Y div CAGR
14.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$3,699.26
Full YZCHF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — YZCHF vs PFE

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodYZCHFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, YZCHF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
YZCHF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YZCHF
Annual income on $10K today (after 15% tax)
$442.11/yr
After 10yr DRIP, annual income (after tax)
$3,144.37/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $19,175.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YZCHF + PFE for your $10,000?

YZCHF: 50%PFE: 50%
100% PFE50/50100% YZCHF
Portfolio after 10yr
$45.2K
Annual income
$14,978.99/yr
Blended yield
33.16%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

YZCHF
No analyst data
Altman Z
1.0
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YZCHF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricYZCHFPFE
Forward yield5.20%6.13%
Annual dividend / share$0.10$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR14.2%13.2%
Portfolio after 10y$40.8K$49.6K
Annual income after 10y$3,699.26$26,258.71
Total dividends collected$17.1K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: YZCHF vs PFE ($10,000, DRIP)

YearYZCHF PortfolioYZCHF Income/yrPFE PortfolioPFE Income/yrGap
1$11,294$593.99$9,153$693.39+$2.1KYZCHF
2$12,801$715.99$8,593$849.25+$4.2KYZCHF
3$14,563$866.11$8,336$1,066.78+$6.2KYZCHF
4$16,634$1,051.64$8,437$1,384.80+$8.2KYZCHF
5$19,080$1,282.03$9,013$1,875.40+$10.1KYZCHF
6$21,985$1,569.54$10,306$2,680.72+$11.7KYZCHF
7$25,454$1,930.21$12,820$4,101.38+$12.6KYZCHF
8$29,621$2,385.17$17,673$6,826.70+$11.9KYZCHF
9$34,657$2,962.40$27,543$12,591.86+$7.1KYZCHF
10← crossover$40,783$3,699.26$49,560$26,258.71$8.8KPFE

YZCHF vs PFE: Complete Analysis 2026

YZCHFStock

Yankuang Energy Group Company Limited engages in the mining, preparation, and sale of coal worldwide. It offers thermal, PCI, and coking coal for electric power, metallurgy and chemical industry, etc.; produces and sells coal chemicals, as well as electricity and related heat supply services; explores for potash mineral; manufactures, installs, repairs, and sells coal mining and excavating equipment, cable, and electrical equipment; and sells construction materials and petroleum products. The company also provides railway, river, and lakes transportation; underground mines management; mining materials testing; equity investment fund and corporate asset management, investment advisory and management, foreign investment fund, import and export, and international trading; solar and wind power, and production management; educational software development and event planning; and coal mining technology development, transfer, and consultation services, as well as operates as a trade broker and agent. In addition, it engages in the wholesale of coal and non-ferrous metals; house and financial leasing; logistics storage and leasing; development of charcoal products; LTCC technology development and equipment rental operations; manufacturing and sale of cable and rubber products; production and processing of steel engineering components; processing, production, and sale of FischerTropsch synthesis catalyst, composite pipe, and plastic profile products; real estate development and operation, property management, garden greening engineering, and sewage treatment and rental housing agency services; and issuing subordinated capital notes. The company was formerly known as Yanzhou Coal Mining Company Limited and changed its name to Yankuang Energy Group Company Limited in December 2021. The company was founded in 1973 and is based in Zoucheng, the People's Republic of China.

Full YZCHF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this YZCHF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YZCHF vs SCHDYZCHF vs JEPIYZCHF vs OYZCHF vs KOYZCHF vs MAINYZCHF vs JNJYZCHF vs MRKYZCHF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.